Your browser is no longer supported. Please, upgrade your browser.
Settings
INSM Insmed Incorporated daily Stock Chart
INSM [NASD]
Insmed Incorporated
Index- P/E- EPS (ttm)-3.88 Insider Own1.00% Shs Outstand74.33M Perf Week8.71%
Market Cap2.01B Forward P/E- EPS next Y-3.71 Insider Trans6.26% Shs Float73.23M Perf Month16.53%
Income-298.10M PEG- EPS next Q-1.06 Inst Own- Short Float14.45% Perf Quarter69.29%
Sales- P/S- EPS this Y-1.60% Inst Trans0.81% Short Ratio10.68 Perf Half Y28.90%
Book/sh3.78 P/B7.16 EPS next Y5.60% ROA-45.50% Target Price36.70 Perf Year12.37%
Cash/sh7.64 P/C3.54 EPS next 5Y- ROE-81.80% 52W Range11.31 - 31.58 Perf YTD106.33%
Dividend- P/FCF- EPS past 5Y-13.20% ROI- 52W High-14.28% Beta3.03
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low139.35% ATR1.15
Employees214 Current Ratio10.10 Sales Q/Q- Oper. Margin- RSI (14)75.86 Volatility3.59% 4.37%
OptionableYes Debt/Eq1.07 EPS Q/Q-64.60% Profit Margin- Rel Volume1.82 Prev Close26.10
ShortableYes LT Debt/Eq1.07 EarningsFeb 22 BMO Payout- Avg Volume991.15K Price27.07
Recom1.90 SMA209.96% SMA5036.98% SMA20025.77% Volume1,772,696 Change3.72%
Feb-15-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $40
Jan-17-19Upgrade Goldman Neutral → Buy
Jan-02-19Initiated Canaccord Genuity Buy $20
Aug-06-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-23-18Initiated Goldman Neutral $32
Apr-23-18Upgrade Credit Suisse Neutral → Outperform
Mar-21-18Initiated Morgan Stanley Overweight $39
Jan-18-18Initiated Credit Suisse Neutral $31
Sep-05-17Reiterated Evercore ISI Outperform $28 → $40
Aug-17-17Initiated Evercore ISI Outperform $28
Jul-11-17Initiated Robert W. Baird Outperform $23
Mar-15-16Initiated Stifel Buy $23
Nov-09-15Downgrade UBS Buy → Neutral $35 → $18
Oct-06-15Reiterated H.C. Wainwright Buy $30 → $35
Jun-09-15Initiated Citigroup Neutral $27
Mar-26-14Reiterated HC Wainwright Buy $25 → $30
Jan-06-14Reiterated UBS Buy $17.50 → $31
Nov-11-13Initiated HC Wainwright Buy $25
Jun-19-13Initiated UBS Buy $17.50
Jun-18-13Initiated UBS Buy $17.50
Feb-15-19 08:00AM  Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019 PR Newswire
Feb-13-19 09:29AM  Is Insmed Incorporateds (NASDAQ:INSM) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Feb-07-19 07:50AM  Market Trends Toward New Normal in lululemon athletica inc, Insmed, Advanced Disposal Services, AGCO, Douglas Dynamics, and Ballard Power Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-04-19 04:05PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Jan-25-19 08:56AM  Options Traders Expect Huge Moves in Insmed (INSM) Stock Zacks +5.62%
Jan-16-19 10:16AM  Top 5 Small-Cap Winners And Losers, Week Of Jan. 7 Benzinga
Jan-12-19 12:00PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-11-19 07:46AM  The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference Motley Fool
Jan-07-19 07:49PM  Here's Why Insmed Rocketed 43% Higher on Monday Motley Fool +43.23%
04:05PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
01:56PM  Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology ETF Trends
Jan-04-19 04:35PM  Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter MarketWatch +6.76%
04:05PM  Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019 PR Newswire
Dec-18-18 11:54PM  Is Insmed Incorporated (INSM) A Good Stock To Buy? Insider Monkey
Dec-04-18 08:30AM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -8.85%
Nov-14-18 11:35AM  Healthcare Stocks with Turnaround Potential ACCESSWIRE
Nov-08-18 08:50AM  Consolidated Research: 2018 Summary Expectations for Insmed, Service Corporation International, EPR Properties, Nielsen Holdings Plc, NiSource, and Criteo S.A Fundamental Analysis, Key Performance Indications GlobeNewswire
08:30AM  Insmed Announces Changes to its Board of Directors GlobeNewswire
Nov-06-18 08:30AM  Insmed to Present at Three November Conferences GlobeNewswire
Nov-05-18 11:09PM  Edited Transcript of INSM earnings conference call or presentation 30-Oct-18 12:30pm GMT Thomson Reuters StreetEvents +5.21%
Nov-02-18 07:15PM  Insmed Inc (INSM) President & CEO William Lewis Bought $249,630 of Shares GuruFocus.com
Oct-30-18 07:45AM  Insmed: 3Q Earnings Snapshot Associated Press -8.07%
07:30AM  Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Oct-23-18 08:30AM  Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018 GlobeNewswire
Oct-16-18 02:46PM  Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +6.64%
Oct-11-18 08:30AM  Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension) GlobeNewswire
Oct-04-18 04:30PM  Insmed Extends Patent Protection in Japan to 2033 GlobeNewswire
Oct-01-18 06:01PM  What Analysts Have To Say About Insmed Following Arikayce Approval Benzinga -22.16%
12:45PM  Here's Why Insmed Slumped Lower Today Motley Fool
11:46AM  Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce Zacks
08:00AM  Insmed to Present at Two October Conferences GlobeNewswire
Sep-28-18 06:36PM  Insmed's treatment-resistant lung disease drug gets FDA approval Reuters -5.25%
05:58PM  Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options GlobeNewswire
05:45PM  Insmed's treatment-resistant lung disease drug gets FDA approval Reuters
Sep-24-18 08:54AM  Is the Options Market Predicting a Spike in Insmed (INSM) Stock? Zacks +5.54%
Sep-17-18 08:00AM  Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine GlobeNewswire
Aug-17-18 07:35AM  Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semiconductor, Changyou, Pain Therapeutics, and Aurinia Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Aug-13-18 01:26PM  The Week Ahead: Nvidia, Retailer Earnings In Focus Benzinga
Aug-08-18 08:15AM  The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict Benzinga -8.95%
Aug-07-18 05:30PM  FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmeds ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options GlobeNewswire
Aug-06-18 03:30PM  The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal Benzinga -6.81%
Aug-04-18 03:19AM  Edited Transcript of INSM earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 11:58AM  Insmed: 2Q Earnings Snapshot Associated Press +13.36%
07:30AM  Insmed Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-26-18 08:00AM  Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018 GlobeNewswire
Jul-13-18 07:30AM  Free Technical Research on Insmed and Three More Biotech Equities ACCESSWIRE
Jun-15-18 08:00AM  Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC GlobeNewswire -5.41%
Jun-07-18 08:00AM  Insmed to Present at Three June Conferences GlobeNewswire
May-30-18 07:50AM  Recent Analysis Shows Northwest Natural Gas, Brooks Automation, Insmed, Host Hotels & Resorts, Prospect Capital, and Inphi Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
May-25-18 08:30AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Insmed ACCESSWIRE
May-23-18 08:15AM  Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing Benzinga
May-22-18 05:15PM  Insmed Announces Presentations at the American Thoracic Society 2018 International Conference GlobeNewswire
May-18-18 07:50AM  Blog Exposure - FDA Accepted for Review Insmeds Marketing Application for ALIS in NTM Lung Disease Caused by MAC ACCESSWIRE
May-17-18 04:05PM  Insmed Appoints Leo Lee to its Board of Directors GlobeNewswire
May-16-18 08:00AM  Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC GlobeNewswire
May-09-18 03:52AM  Edited Transcript of INSM earnings conference call or presentation 2-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-08-18 08:43PM  Insmed Incorporated (NASDAQ:INSM): Is Breakeven Near? Simply Wall St.
May-03-18 08:30AM  Today's Research Reports on Trending Tickers: Insmed and Arena Pharmaceuticals ACCESSWIRE -5.11%
May-02-18 09:18AM  Insmed: 1Q Earnings Snapshot Associated Press +9.50%
07:30AM  Insmed Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
May-01-18 08:00AM  Insmed to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
Apr-25-18 08:00AM  Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018 GlobeNewswire
Apr-23-18 12:20PM  Insmed Shares To Outperform Through 2018 After 'Slow Start,' Credit Suisse Says In Upgrade Benzinga +10.76%
Apr-10-18 07:42AM  Insmed (INSM): Moving Average Crossover Alert Zacks +6.34%
Apr-05-18 08:00AM  Research Report Identifies Brown & Brown, CorVel, Pacific Ethanol, HomeTrust Bancshares, FORTERRA INC, and Insmed with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-03-18 08:00AM  Todays Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed ACCESSWIRE
07:20AM  Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease ACCESSWIRE
Mar-29-18 08:00AM  Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC GlobeNewswire
Mar-21-18 09:54AM  Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley Benzinga
Mar-14-18 09:02PM  Insmed Incorporated (NASDAQ:INSM): Will The Growth Last? Simply Wall St.
Mar-07-18 08:00AM  Insmed to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 07:42AM  New Strong Sell Stocks for March 1st Zacks
Feb-27-18 02:11PM  Edited Transcript of INSM earnings conference call or presentation 23-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
Feb-23-18 07:53AM  Insmed reports 4Q loss Associated Press +5.98%
07:30AM  Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire
06:45AM  Insmed Incorporated to Host Earnings Call ACCESSWIRE
Feb-21-18 05:26PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-20-18 08:00AM  Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent GlobeNewswire
Feb-15-18 08:00AM  Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018 GlobeNewswire
Feb-12-18 07:40AM  Market Trends Toward New Normal in Insmed, Hudson Technologies, East West, Ringcentral, Armstrong Flooring, and Host Hotels & Resorts Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-07-18 04:30PM  Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-26-18 12:00PM  Insmed Announces Closing of Public Offering GlobeNewswire
Jan-24-18 05:31PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-23-18 10:49PM  Insmed Announces Pricing of Public Offering of Convertible Senior Notes GlobeNewswire -6.01%
Jan-22-18 04:01PM  Insmed Announces Proposed Public Offering of Convertible Senior Notes GlobeNewswire +5.40%
Jan-05-18 03:00PM  With A -40.65% Earnings Drop Lately, Did Insmed Incorporated (NASDAQ:INSM) Underperform Its Industry? Simply Wall St.
Jan-03-18 04:10PM  Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations GlobeNewswire
Jan-02-18 08:05AM  See what the IHS Markit Score report has to say about Insmed Inc. Markit
Dec-28-17 03:55PM  How Financially Strong Is Insmed Incorporated (NASDAQ:INSM)? Simply Wall St.
Dec-25-17 08:05AM  See what the IHS Markit Score report has to say about Insmed Inc. Markit
Dec-12-17 08:30PM  Barron's After Hours: Insmed Soars, Western Digital Jumps, VeriFone Slumps Barrons.com
Dec-01-17 08:10AM  Todays Research Reports on Stocks to Watch: Horizon Pharma and Insmed Incorporated ACCESSWIRE
Nov-30-17 03:41PM  Insmed, Inc. Fundamental Analysis : November 30, 2017 Capital Cube +6.38%
Nov-28-17 08:00AM  Insmed to Present at the Nasdaq 37th Annual Investor Conference GlobeNewswire
Nov-27-17 08:03AM  See what the IHS Markit Score report has to say about Insmed Inc. Markit
Nov-22-17 04:30PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:02AM  See what the IHS Markit Score report has to say about Insmed Inc. Markit
Nov-20-17 08:07AM  See what the IHS Markit Score report has to say about Insmed Inc. Markit
Nov-17-17 08:03AM  See what the IHS Markit Score report has to say about Insmed Inc. Markit
Nov-16-17 08:10AM  Todays Research Reports on Stocks to Watch: Juno Therapeutics and Insmed Incorporated ACCESSWIRE
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALTOMARI ALFREDDirectorFeb 05Sale25.005,500137,50036,942Feb 07 04:07 PM
ALTOMARI ALFREDDirectorJan 10Sale22.505,500123,75042,442Jan 14 04:15 PM
SHAROKY MELVIN MDDirectorNov 12Buy15.598,795137,11020,000Nov 13 04:03 PM
SHAROKY MELVIN MDDirectorNov 09Buy16.3411,205183,10211,205Nov 13 04:03 PM
ENGELSEN STEINAR JDirectorNov 01Buy15.7916,085253,993281,303Nov 02 04:07 PM
Adsett RogerChief Commercial OfficerNov 01Buy15.973,00047,90718,594Nov 02 04:07 PM
Lewis WilliamPresident & CEONov 01Buy15.9015,700249,600151,247Nov 02 04:06 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerMay 30Option Exercise10.8525,991282,00236,660May 31 04:05 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerMay 30Sale28.2425,991733,98610,669May 31 04:05 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerMay 29Option Exercise10.8511,584125,68622,253May 31 04:05 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerMay 29Sale27.6811,584320,64510,669May 31 04:05 PM